CARsgen Therapeutics to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress

Reuters

2025/10/06

CARsgen <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress

CARsgen Therapeutics Holdings Ltd. has announced that it will present updated clinical data for CT0596, its allogeneic BCMA-targeted CAR-T cell therapy, at the 67th Annual Congress of the American Society of Hematology $(ASH)$ in 2025. The abstracts and further details regarding the presentation are scheduled for release after November 3, 2025 (Eastern Time). CT0596, developed using CARsgen's THANK-u Plus™ platform, is currently being evaluated in investigator-initiated trials for patients with relapsed/refractory multiple myeloma and plasma cell leukemia. The company reports that the therapy has demonstrated preliminary favorable tolerability and encouraging efficacy signals at all tested dose levels. CARsgen also plans to further investigate CT0596 in other plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells, and anticipates submitting an Investigational New Drug (IND) application in the second half of 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573644149"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573644149\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573644149?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 08:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573644149","market":"nz","top_or_hot":-1,"title":"CARsgen Therapeutics to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CARsgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CARsgen Therapeutics Holdings Ltd. has announced that it will present updated clinical data for CT0596, its allogeneic BCMA-targeted CAR-T cell therapy, at the 67th Annual Congress of the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> in 2025. The abstracts and further details regarding the presentation are scheduled for release after November 3, 2025 (Eastern Time). CT0596, developed using CARsgen's THANK-u Plus™ platform, is currently being evaluated in investigator-initiated trials for patients with relapsed/refractory multiple myeloma and plasma cell leukemia. The company reports that the therapy has demonstrated preliminary favorable tolerability and encouraging efficacy signals at all tested dose levels. CARsgen also plans to further investigate CT0596 in other plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells, and anticipates submitting an Investigational New Drug (IND) application in the second half of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARsgen Therapeutics to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARsgen Therapeutics to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-06 08:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CARsgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CARsgen Therapeutics Holdings Ltd. has announced that it will present updated clinical data for CT0596, its allogeneic BCMA-targeted CAR-T cell therapy, at the 67th Annual Congress of the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> in 2025. The abstracts and further details regarding the presentation are scheduled for release after November 3, 2025 (Eastern Time). CT0596, developed using CARsgen's THANK-u Plus™ platform, is currently being evaluated in investigator-initiated trials for patients with relapsed/refractory multiple myeloma and plasma cell leukemia. The company reports that the therapy has demonstrated preliminary favorable tolerability and encouraging efficacy signals at all tested dose levels. CARsgen also plans to further investigate CT0596 in other plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells, and anticipates submitting an Investigational New Drug (IND) application in the second half of 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1585","symbol_name":"昨日強勢股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDLc9kmnx:1","article_id":"2573644149","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573644149","pubTimestamp":1759709175,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1585":"昨日强势股","BK1587":"次新股","02171":"科济药业-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"科济康将在ASH 2025年年会上展示同种异体BCMA CAR-T疗法CT0596的有希望的临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":0.9},"content_text":"CARsgen Therapeutics to Present Promising Clinical Data for Allogeneic BCMA CAR-T Therapy CT0596 at ASH 2025 Annual Congress\n    \n\n        CARsgen Therapeutics Holdings Ltd. has announced that it will present updated clinical data for CT0596, its allogeneic BCMA-targeted CAR-T cell therapy, at the 67th Annual Congress of the American Society of Hematology $(ASH)$ in 2025. The abstracts and further details regarding the presentation are scheduled for release after November 3, 2025 (Eastern Time). CT0596, developed using CARsgen's THANK-u Plus™ platform, is currently being evaluated in investigator-initiated trials for patients with relapsed/refractory multiple myeloma and plasma cell leukemia. The company reports that the therapy has demonstrated preliminary favorable tolerability and encouraging efficacy signals at all tested dose levels. CARsgen also plans to further investigate CT0596 in other plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells, and anticipates submitting an Investigational New Drug (IND) application in the second half of 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief on October 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}